STAAR Surgical designs and manufactures implantable lenses for vision correction, most notably its EVO Implantable Collamer Lens (ICL) used as a surgical alternative to corneal laser procedures for many patients with myopia and related refractive errors. The company sells through ophthalmic surgeons and clinics worldwide rather than as a consumer retail brand. Its niche is specialty refractive implants instead of general cataract IOLs alone.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 44.3 | — | -16.8 | — |
| Q3 2025 | 94.7 | — | 8.9 | — |
| Q4 2025 | 57.8 | — | -18.3 | — |
| Q1 2026 | 93.5 | — | 5.2 | — |
| Q2 2026 | 93.5 | 111% | 8.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Power Solutions International, Inc. (PSIX), Karat Packaging Inc. (KRT), Five Star Bancorp (FSBC), Upwork Inc. (UPWK), Avalyn Pharma Inc. (AVLN), Marten Transport, Ltd. (MRTN)